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Abstract  
Diagnostic application of array-CGH in PGD for reciprocal and Robertsonian 
translocations has revealed 55-65% embryos with additional aneuploidies with 
or without translocation related imbalances. The occurrence of extra 
abnormalities with translocations reduces the number of embryos suitable for 
transfer. This study followed up 83 embryos on day 5-7 of development from 
23 infertile or sub-fertile carriers for whole chromosome and segmental 
aneuploidies present in addition to the balanced or unbalanced translocations 
detected on aCGH diagnosis. Embryos were analysed by FISH (63) and 
aCGH (20). Meiotic aneuploidy affected 35% of embryos and 47% had mitotic 
events; 15% had both types. In total, meiotic and mitotic events were almost 
equal (60 versus 64), 97 affected whole chromosomes (58 meiotic, 39 mitotic)  
and 27 were segmental (2 meiotic, 25 mitotic). In 85.5% of embryos with 
whole chromosome additional aneuploidies, either the aneuploidy was 
present throughout or in more than 50% of cells. All embryos diagnosed as 
abnormal (translocation balanced or unbalanced) after aCGH diagnosis at 
cleavage stage would have remained unsuitable for transfer if tested at later 
stages of development. Additional aneuploidies, whether segmental or 
affecting whole chromosomes, are important findings and merit full 
consideration when considering the choice of embryos to transfer. 
 
Keywords: aCGH; reciprocal translocations; aneuploidies; mitotic; meiotic  
Introduction 
According to cytogenetic studies of newborn infants carried out on 63,000 
individuals from six different countries the combined incidence of balanced 
Robertsonian and reciprocal translocations lies between 1.5 and 1.7 per 
thousand (Jacobs, 1977; Maeda et al., 1991).  As adults, most of these 
individuals are able to reproduce successfully, with the help of prenatal 
diagnosis where necessary. A minority will experience overt fertility problems 
leading them to present for investigation and to consider preimplantation 
genetic diagnosis (PGD). PGD was first made available in 1995 for couples at 
risk of chromosomally abnormal conceptions arising from the translocation 
carrier status of one partner (Conn et al., 1995). The approach employed the 
technique of fluorescence in situ hybridisation (FISH) with chromosome 
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probes specific to regions that had been translocated. Other publications soon 
followed (Conn et al., 1998; 1999; Munné et al., 1998; Scriven et al., 1998; 
Iwarsson et al., 2000). Later in some centres, additional probes were added to 
screen for common aneuploidies, but the main focus was on the translocated 
chromosomes. The development of techniques to allow the application of 
comparative genomic hybridisation (CGH) analysis to single cells paved the 
way to the comprehensive screening of all chromosomes (Wells et al., 2000; 
Voullaire et al., 2000). Initially, this approach required a high degree of skill 
and a lengthy period of hybridisation, so it was the advent of single cell CGH 
analysis via microarrays (aCGH) that opened up the field and reports of its 
application in translocation PGD cycles rapidly appeared (Alfarawati et al., 
2011; Fiorentino et al., 2011).  It quickly became apparent that additional 
aneuploidies were as common as translocation imbalances (Alfarawati et al., 
2011; Fiorentino et al., 2011). At that time, most cases involved day 3 biopsy 
of blastomeres, a minority were diagnosed on trophectoderm (TE) samples. 
Most centres avoided the transfer of any embryo with a chromosomal 
anomaly but a few decided to consider only the translocation imbalances. The 
reasoning behind this was that the true extent of any additional aneuploidies 
was unknown since most were diagnosed on a single cell. There have been 
few reports of any follow up analyses to answer this question. In a validation 
study, Colls et al. (2012) re-analysed by FISH embryos diagnosed as 
abnormal by aCGH; of 102 embryos (not all from translocation cases) 52 were 
uniformly aneuploid and 45 were aneuploid mosaic or chaotic mosaic – but 
with all cells abnormal. Follow up analysis was also carried out by Fiorentino 
et al. (2011); embryos diagnosed as abnormal were re-biopsied on day 6 and 
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the cells subjected to analysis identical to that employed for diagnosis. In 
total, 57 embryos with additional aneuploidies, with or without translocation 
imbalance, were re-analysed and the diagnoses confirmed. Aneuploidy 
mosaicism was seen in 24/57 embryos but all were confirmed as abnormal 
despite the mosaicism; no details were given.  
The aim of our study was to investigate in detail the significance of 
aneuploidies that occur in addition to translocation imbalances in couples 
undergoing PGD via aCGH and to determine whether the origin was meiotic 
or mitotic.  
 
Methods 
Patient information and details of PGD cycles 
PGD via aCGH was performed on embryos from couples that included 16 
carriers of reciprocal translocations and 7 carriers of Robertsonian 
translocations.  For all the treatment cycles, ICSI (intracytoplasmic sperm 
injection) was carried out to limit paternal contamination.  One or two 
blastomeres were biopsied on day 3 post-fertilisation in 29 PGD cycles and 
TE cells were biopsied on day 5 in two cycles. 24Sure™ arrays (BlueGnome 
Ltd., now Illumina) were used for the detection of Robertsonian translocations 
and 24Sure+™ (BlueGnome Ltd., now Illumina) arrays were used for 
reciprocal translocations.  Embryos with balanced forms of the translocation 
and no other aneuploidies were recommended for transfer. Embryos 
unbalanced for the translocation and/or with additional aneuploidies were 
considered unsuitable for transfer and were collected on day 5-7 post-
fertilisation for follow-up analysis. The average maternal age was 35 ±4.2 
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years. Table 1 provides the patient details, which include the karyotypes of 
the carriers along with the reproductive histories of the couples and the 
maternal ages. Information about the number of embryos biopsied and the 
number of transferrable embryos for each PGD cycle is also provided.  
 
Processing of untransferred embryos and allocation of embryos for 
follow up. 
Embryos unsuitable for transfer were processed immediately after collection. 
The morphology of the embryos was noted at the time of processing. Whole 
embryos were either spread on microscopic slides for FISH or tubed (in 0.2μl 
microcentrifuge tubes) for aCGH analysis. Untransferred embryos with one to 
five distinct additional abnormalities were followed up; embryos with multiple 
chromosome abnormalities (> five aneuploidies) and embryos with no 
diagnostic results were excluded. 
 
Clinical and research approvals 
Diagnosis and follow up was covered by the treatment licence (licence 
reference R0113-7-a, valid 27/11/13 to 26/11/16) from the HFEA (Human 
Fertilisation and Embryology Authority) held by the CRGH (Centre for 
Reproductive and Genetic Health). UCL Centre for PGD is an accredited 
laboratory (Clinical Pathology Accreditation, reference no. 2920). 
 
 
Spreading of untransferred embryos and FISH procedure 
Whole untransferred embryos were spread using the Tween-HCl method as 
described in Harper et al. (1994). The FISH protocol was performed as 
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previously described with slight modifications (Harper et al., 1994). FISH 
probes were chosen to follow up those chromosomes, unrelated to the 
translocation, that were identified as aneuploid on diagnosis. A combination of 
CEP (chromosome enumeration probes), Sub-tel (sub-telomeric probes) and 
LSI (locus specific identifier probes) in different fluorochromes was suitably 
selected. All probes were from Abbott Molecular, UK.  
Microscope analysis and scoring of FISH signals  
The slides were examined under an epifluorescence Olympus microscope 
(Olympus BX 40) equipped with suitable filters. Specific signal scoring criteria 
were applied to interphase nuclei for uniform evaluation of FISH signals, in 
accordance with Hopman et al., 1988 and Mantzouratou et al., 2007. 
 
Tubing of untransferred embryos for aCGH analysis 
Whole untransferred embryos were tubed under sterile conditions. Under a 
dissecting microscope using 0.3μm microcapillary (Sartorius, UK), the 
embryos were transferred from the IVF culture dish into drops of 1XPBS 
(phosphate buffered saline)/0.1%PVA (Polyvinyl alcohol) (Sigma, UK) solution 
in a petri dish. By repeated pipetting using a smaller 0.2μm microcapillary the 
embryonic cells were detached from the zona pellucida. The cells were then 
washed in a fresh drop of PBS/0.1%PVA and transferred into sterile 0.2ml 
microcentrifuge tubes with a minimal amount of solution.  
 
Whole Genome Amplification (WGA) and aCGH analysis 
The whole genome of the embryonic cells was amplified using the Sureplex™ 
amplification kit (BlueGnome Ltd., now Illumina) following the manufacturer’s 
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protocol. Amplification efficiency was checked by gel electrophoresis.  
Samples that successfully amplified had DNA smears of fragment size 
ranging between 100 and 1000 bp (base pairs) with a median size of 400 bp. 
 
The untransferred embryos were subjected to follow-up by aCGH using two 
different array platforms. Some embryos were analysed by BlueGnome 
24Sure™/24Sure+™ BAC (bacterial artificial chromosome) arrays. 24Sure+™ 
high density BAC arrays include ~4800 clones spaced at 623Kb intervals 
across the human genome. The remaining embryos were subjected to follow-
up by Agilent’s 8x60K high-resolution oligonucleotide arrays (Agilent 
Technologies, UK). These high-density arrays included ~55,000, 60-mer 
oligonucleotides spaced at an average of 41kb intervals across the human 
genome (Design ID 021924). BlueGnome 24Sure/24Sure+ arrays were 
previously validated in our laboratory for clinical use. Validation was 
performed on 35 single cells from cell lines with known karyotypes (Mamas et 
al., 2012). The 8x60K oligonucleotide arrays were also validated in house on 
single blastomeres and embryos previously analysed by BAC arrays before 
employing them for follow-up purposes.  
 
 
 
Array-CGH diagnosis and follow up using BlueGnome 24Sure/24Sure+ 
BAC arrays 
Array-CGH using 24Sure (v2 and v3) or 24Sure+ arrays was performed 
according to the manufacturer’s instructions. Briefly, test samples were 
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labeled with Cy3 and reference samples with Cy5 fluorophores. Labeling was 
carried out for 16-18 hours. Combination, ethanol precipitation and 
denaturation were performed on the following day and the samples were 
hybridized for 3-4hrs. The slides were washed and scanned using InnoScan 
700 (Innopsys SA) or ScanArray Express (Perkin Elmer) or Agilent SureScan 
microarrays (Agilent Technologies) scanners at a resolution of 10µm and 
scanned images were analysed and interpreted using the BlueFuse Multi 
software (BlueGnome Ltd, now Illumina). The BlueFuse algorithm is based on 
calculating the median log2ratio of all the chromosomes for detection of gains 
and losses. A median log2ratio value ≥ 0.3 indicated chromosome gains 
whereas values ≤ –0.3 indicated chromosome losses. Gains and losses of 
segmental (partial) aneuploidies unrelated to the translocation were identified 
when a minimum of 10 consecutive BAC clones crossed the normality 
thresholds.  
 
Array-CGH follow up with Agilent’s 60-mer oligonucleotide microarrays 
Eight embryonic samples after WGA were tested using both the high-
resolution Agilent (8x60K) 60-mer oligonucleotide microarrays and 
BlueGnome BAC (bacterial artificial chromosome) 24Sure/24Sure+ 
microarrays. The manufacturer’s protocol was used to perform the Agilent 
8x60K oligo microarrays with certain modifications.  Briefly, test samples were 
labeled with Cy5 and reference samples with Cy3 fluorophores. Labeling of 
the amplified DNA was carried out for 2.5 hours. Preparation for hybridization 
included combination, ethanol precipitation and denaturation, performed on 
the same day. Hybridisation was carried out overnight for 16 hours. 
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Microarray washing was performed the following day. The arrays were 
scanned using Agilent SureScan Microarray Scanner at 3μm and the TIFF 
images analysed using Agilent Genomic Workbench 7.0 (Agilent 
technologies). All samples were analysed by a single cell analysis method 
recommended by the manufacturer. The analysis method was configured with 
ADM-2 (Aberration Detection Method 2). This algorithm identified all aberrant 
intervals in the sample with consistently high or low log2ratios based on a 
statistical score.  The software identified the aberrations if the average 
log2ratio of the sample over the reference exceeded a specific threshold; 
log2ratio of ≥0.3 for gains and ≥0.55 for losses. 
Classification of embryos according to their mechanism of origin of 
aneuploidy post FISH and aCGH follow-up analysis 
The embryos were classified as having mitotic or meiotic aneuploidy events 
based on the extent of aneuploidy seen in the embryos either by FISH or 
aCGH follow-up. Aneuploidy was recorded based on the number of 
aneuploidy events per chromosome per embryo analysed excluding the 
chromosomes associated with the translocation. 
 
 
 
 
Follow up by FISH 
Embryos were classified as having a mitotic aneuploidy event when the 
embryos were mosaic with at least two cell lines, a diploid cell line and an 
aneuploid cell line or two different aneuploid cell lines. The imbalance of the 
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aneuploid cell line could be either concordant with that detected at clinical 
diagnosis (day 3/day 5) or a complementary gain or loss.  The percentages of 
nuclei with the diploid and aneuploid cell lines for a single aneuploidy event 
were calculated. 
Embryos were classified as having a meiotic aneuploidy event when over 
90% of nuclei were scored in concordance with the aneuploidy scored at 
diagnosis. This is based upon our experience in following up the imbalances 
related to the translocation in the rest of the embryo; although it is known that 
the translocation related imbalances are meiotic and should be present in all 
of the embryonic nuclei, this is not always the case. The discrepancy rate may 
be up to 10%; the causes include technical difficulties with the FISH 
procedure and mosaicism. 
 
Follow up by aCGH 
If the aneuploidy event was seen on aCGH diagnosis and not seen on follow-
up or if the aneuploidy event was seen on follow-up and not seen on biopsy, it 
was considered as being mitotic in origin. If the aneuploidy event was seen on 
diagnosis and on follow-up with no indication of mosaicism (deviation of all the 
clones/oligonucleotides belonging to one chromosome between the log2 ratio 
of zero and the normality thresholds in either direction), it was considered as 
being meiotic in origin.  
Results 
Overall summary of diagnostic data  
Twenty-two PGD cycles were performed for 16 carriers of reciprocal 
translocations and 9 PGD cycles for 7 carriers of Robertsonian translocations 
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using aCGH. A total of 298 embryos was tested, [272 after biopsy of one/two 
cells on day 3 and 26 after TE biopsy on day 5], of which 271 (91%) gave 
results. Of the embryos tested, 42 (14%) were either normal or balanced for 
the translocation with no other anomalies and were transferrable. Of the 256 
untransferrable embryos, 170 (170/271, 63%) had been diagnosed with 
additional aneuploidies. Embryos were classified according to Table 2.  Of the 
27 embryos included in the no result group of embryos, 24 had amplification 
failure [24/298 (8%)] and were not processed further. Additionally, 1% 
embryos did not give a conclusive result (3/298). 
 
Embryos for FISH and aCGH follow up of additional aneuploidies 
Of the 112 embryos with 1-5 additional aneuploides, 63 were followed up by 
FISH and 22 by aCGH, in total 85. The remaining 27 embryos were regarded 
as unsuitable for follow up for various reasons.  
 
Overall summary of follow up data 
Conclusive follow up results were obtained for 83 out of 85 embryos, 63 by 
FISH and 20 by aCGH. Of the 85 aneuploid embryos, 30 (35.29%) had only 
meiotic errors and 40 (47.06%) had only mitotic errors, 13 (15.29%) embryos 
had both type of errors and 2 (2.35%) embryos did not give results (Figure 1). 
In total, meiotic and mitotic events were almost equal (60 versus 64), 97 
affected whole chromosomes (58 meiotic, 39 mitotic) and 27 were segmental 
(2 meiotic, 25 mitotic). Of the 97 whole chromosome aneuploidies followed 
up, 90 (92.8%) persisted to later stages. Whereas for the segmental 
anomalies, out of the 27, only 12 (44%) were seen at later stages.  
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However of those followed up by FISH, 10/13 were detected on follow up, 
whereas of those analysed by aCGH 2/14 were detected on follow up (both 
mitotic and meiotic events included). The difference between the two may be 
due to the high frequency of MND detected after FISH follow up, as discussed 
later. 
Results from embryos with FISH follow up 
Follow-up by FISH included 48 embryos from PGD for reciprocal translocation 
cycles and 15 embryos from Robertsonian translocation cycles. In all, the 63 
embryos presented with 100 additional aneuploidy events at diagnosis, 86 
whole chromosomal and 14 segmental aneuploidies. Follow up was 
performed for 93/100 events (93%) (Figure 2).  
 
Classification of chromosome aneuploidy events post follow up by FISH 
In 63 untransferred embryos, 80 whole chromosome and 13 segmental 
additional aneuploidy events were re-analysed. Forty-four whole chromosome 
meiotic aneuploidy events were found (Figure 2). Among these, 28/44 (64%) 
were uniformly aneuploid meiotic events in which all the embryonic nuclei had 
FISH signals consistent with the aneuploidy detected on diagnostic aCGH and 
for 16/44 (36%) the embryo had over 90% nuclei with FISH signals consistent 
with the aneuploidy detected on diagnosis and were also considered to be 
meiotic in origin. Only one segmental meiotic event was present after follow 
up in one embryo, this being the loss of 2q11.2-2qter in an arrested embryo 
with 9 cells.  
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Thirty-six whole chromosome and 12 segmental mitotic aneuploidy events 
were found (Figure 2). Embryos with mitotic errors were either 
diploid/aneuploid mosaics or aneuploid mosaics. Regarding whole 
chromosome errors, in sixteen events, the aneuploidy event present on 
diagnosis was confirmed on follow up. In fourteen other cases, the embryo 
contained two different cell lines showing complementary aneuploidy events 
(for example: +9, -9) presumably due to mitotic non-disjunction (MND) one of 
which was present on diagnostic aCGH. Additionally six whole chromosome 
events in five embryos were not seen on follow up but in all these embryos 
other anomalies were present.  
 
Similarly, follow up data of the twelve segmental mitotic aneuploidies showed 
that three segments in three embryos were not seen on follow up.  Six events 
with complementary findings presumably arose due to MND and the 
remaining three showed aneuploid cells between 11%-30% after FISH follow 
up. 
 
Results of embryos with aCGH follow up 
Validation results of eight embryonic samples showed that the BAC and the 
oligonucleotide-based arrays gave comparable results. A total of 22 whole 
embryos were subjected to WGA. Successful amplification was obtained for 
21/22 (95%) embryos and conclusive aCGH follow up results were obtained 
for 20/21 (95%). Eleven embryos were analysed by BlueGnome 
24Sure/24Sure+ arrays, eight by Agilent 8x60K and two were analysed by 
both BAC and oligonucleotide arrays (one of which was a part of the 
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validation). Follow up by aCGH included seventeen embryos from reciprocal 
and five from Robertsonian translocation carriers. After aCGH follow up, the 
translocation status was confirmed for all 20 embryos with conclusive results. 
 
The aCGH results of twenty embryos are summarised in Figure 3. Overall, of 
the 31 aneuploidies seen on diagnosis only 1 of 17 whole chromosome 
anomalies was not seen on follow up whereas only 1 of 14 segmental errors 
was detected in the whole embryo. Two embryos showed evidence for MND, 
involving two whole chromosomes in one case and one segmental anomaly in 
the other. Figures 4 and 5 provide examples of aCGH results of embryos 
followed up by BAC and oligonucleotide arrays.  
 
Combination of FISH and aCGH follow up data  
Information about additional aneuploidies on diagnosis and follow up was 
therefore available for 83 embryos; 63 whole embryos analysed by FISH and 
20 by aCGH. Follow up data showed that the 124 aneuploid events unrelated 
to the translocation involved all chromosomes with the exception of 
chromosomes 4 and Y.  Figure 6 shows chromosomes 19,16,22,15 and 2 to 
be frequently aneuploid. Most meiotic events were found for chromosome 22 
followed by 15,16 and 19. Chromosome 19 had the highest number of mitotic 
events followed by chromosomes 2, 3 and 16.  
 
In 17 embryos, 22 aneuploid events (7 whole chromosome and 15 segmental) 
seen on diagnosis were not detected in the rest of the embryo on follow up. 
However, these 17 embryos all showed abnormalities related to the 
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translocation and/or other additional abnormalities. The remaining 102/124 
(82%) aneuploid events were either concordant with the aneuploidy seen on 
diagnosis or showed a complementary aneuploid event due to mitotic non-
disjunction.  The majority of the untransferred embryos included in follow up 
analysis were at various stages between the morula and blastocyst stage of 
embryo development.  
 
Mitotic versus Meiotic errors  
In 63 embryos with 93 aneuploid events subjected to follow up by FISH, 45 
meiotic and 48 mitotic events were detected. In 20 embryos with 31 aneuploid 
events subjected to follow up by aCGH, 16 mitotic and 15 meiotic aneuploid 
events were detected. Therefore in a total of 83 embryos with 124 additional 
aneuploid events, which were seen on diagnosis and followed up, 60 (48%) 
meiotic and 64 (52%) mitotic events were found.  Of the meiotic events, 58 
affected whole chromosomes and 2 were segmental. 
 
Proportion of embryos with aneuploidy events 
Whole chromosome abnormalities only were seen in 59 embryos (71%) and 
segmental aneuploidies alone in 14 (17%). Ten embryos (12%) had both 
whole chromosome and segmental anomalies. Excluding the 58 embryos with 
more than 5 errors, but including the 42 transferable embryos and those with 
translocation errors only (59) as well as those followed up, from our diagnostic 
cohort (83), 43/184 (23%) embryos had a meiotic error leading to an 
additional aneuploidy. This is a minimal estimate since some of the multiple 
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anomalies not followed up may have had a meiotic origin; also cases of 
trisomic rescue may appear to be mitotic in origin when they are truly meiotic. 
 
Notably, in our data, 85.5% (59/69) of embryos with whole chromosome 
additional aneuploidies showed an extensive number of abnormal cells; either 
the aneuploidy was present throughout or in more than 50% of cells.  
Discussion 
We have shown that additional whole chromosome aneuploidies detected by 
aCGH diagnosis on embryonic material from translocation carrier parents 
persist and are widespread in 85.5% of embryos that are followed up. We 
found that overall meiotic and mitotic events were almost equal. For the whole 
chromosome aneuploidies meiotic errors predominated whereas for 
segmental anomalies, almost all were mitotic. 
 
Moreover, none of the embryos with additional aneuploidies in our series were 
suitable for transfer; even in cases where the original aneuploidy was no 
longer detectable, other anomalies were present. The additional aneuploidies 
are therefore very important diagnostically. We have also confirmed that 
although diagnosis on TE samples may be preferred, for those couples 
unlikely to have several blastocysts for analysis blastomere diagnosis on day 
3 is still a reliable approach since anomalies seen then are real and very likely 
to be persistent.  
 
It is of considerable interest that the majority of whole chromosome 
aneuploidies have a meiotic origin.  Further work is needed to determine the 
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parental origin of these anomalies and whether they originate in the carrier or 
non-carrier parent. The great majority (20/23) of couples in our study 
presented as infertile or sub-fertile; this may provide a causal link with the 
high frequency of additional meiotic errors.  It is well known that men with 
severe sperm abnormalities show increased levels of aneuploidy (Harton et 
al., 2012). Less well known is the fact that female translocation carriers have 
a reduced reproductive lifespan, increasing the risk of additional aneuploidy at 
a relatively young age (Burgoyne et al.,1985; Setterfield et al., 1988; 
Burgoyne et al., 2009). Also, pre-meiotic or meiotic errors may be increased in 
some individuals due to their genetic background; this may include germline 
mosaicism (Ghevaria et al., 2014). 
 
Our results regarding the overall aneuploidy rate and the frequency of meiotic 
errors are broadly comparable to those of Fragouli et al., (2011).  In this 
investigation the group analysed 52 good quality blastocysts donated by 
women undergoing routine infertility treatment. The average maternal age 
was 36 years, whereas for our group it was 35 years. Thirty embryos (60%) 
had at least some aneuploid cells compared with 63% of our total diagnostic 
cohort, and 30% had a meiotic error (mostly single errors) whereas 23% of 
ours did, but the meiotic error rate per embryo was 0.36 (19/52) for the 
Fragouli et al. (2011) study and 0.32 (60/184) for ours. So it appears that the 
non-translocation aneuploidy rate in our group of patients that were referred 
for PGD because of their translocation carrier status is very much in line with 
that for couples undergoing routine IVF treatment, reflecting the infertile or 
sub-fertile status of our patients. 
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Regarding the segmental anomalies, in comparison to our study, in the study 
published by Fragouli et al., (2013), the authors analysed a large number of 
embryos at different stages of preimplantation development in patients 
undergoing PGS. They found that segmental anomalies occur at a reduced 
frequency in oocytes (4%) and then are found at an appreciable level at 15% 
of cleavage stage embryos and then reducing to 8% at the blastocyst stage. 
Hence the segmental anomalies found in the present study are comparable to 
their study in the incidence of segmental aneuploidies at cleavage stage 
compared with blastocyst stage.  
 
As expected, in our data, the post-zygotic segmental anomalies were nearly 
all mitotic and appeared to be subject to loss in most cases with subsequent 
cell division cycles.  Segments will be lost unless they include a centromere or 
are attached to another chromosome, (Wells et al., 2000; Fragouli et al., 
2013). However, closer analysis revealed that half (6/12) of the mitotic 
segmental anomalies detected on follow up by FISH (as well as 14/36 of the 
whole chromosome mitotic errors) were the outcome of mitotic non-disjunction 
(MND) as a result of random segregation of the fragment  (see Wells et al., 
2000 for a good illustration via metaphase CGH).  While segmental 
imbalances of this nature will continue to be detected after follow up by FISH 
analysis, aCGH follow up may not detect them if the gains and losses are 
approximately equal; this is a possible reason for the much lower rate of 
detection of segmental anomalies in the embryos that were followed up by 
aCGH. So it is entirely possible that many of the segmental anomalies 
originally detected on routine diagnosis by aCGH do persist until later stages 
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of development and should be taken seriously for diagnostic purposes. The 
existence of segmental anomalies, or whole chromosome anomalies, that are 
balanced by MND and are therefore not detected by initial aCGH diagnosis, 
may explain why some blastocysts that are given a normal diagnostic result 
fail to implant. 
 
In conclusion, our data on the source and significance of aneuploidies 
additional to those affecting the translocation chromosomes obtained by the 
follow up of embryos after aCGH diagnosis show that these extra anomalies, 
both whole chromosome and segmental, merit full consideration when 
considering the choice of embryos to transfer. 
 
 
 
 
 
 
 
 
Figure Captions 
Figure 1 Classification of embryos after follow up of diagnostic aneuploid 
events occurring in addition to any translocation related imbalances. 
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Figure 2 Summary of data obtained after follow up by FISH of 63 
untransferred embryos from translocation carriers with additional 
aneuploidies.  MND = Mitotic Non-Disjunction 
 
Figure 3 Summary of data obtained after aCGH follow up of 20 untransferred 
embryos from translocation carriers with additional aneuploidies.  MND = 
Mitotic Non-Disjunction 
 
Figure 4 aCGH follow up result of an embryo from a balanced carrier of a 
reciprocal translocation 46,XY, t(4;12)(q25;q24.31). The blue arrows indicate 
imbalances related to the translocation. The red arrow indicates additional 
aneuploidy, unrelated to the translocation. (A) Diagnostic result using 
24Sure+ (BAC) array : gain of 4p; loss of 12p ; loss of 22 (two cleavage 
blastomeres). (B) Follow up result using 8x60K (oligo) array: gain of 4p; loss 
of 12p; loss of 22 (rest of the embryo). The loss of 22 is a whole chromosome 
loss classed as meiotic as it was present on diagnosis and was detected in 
the rest of the embryo on follow up.  
 
 
 
 
 
Figure 5 aCGH follow up result of an embryo from a balanced carrier of a 
reciprocal translocation 46,XY,t(1;13)(p34.3;q34). (A) Diagnostic result using 
24Sure+ BAC arrays: Balanced for the translocation chromosomes; loss of 21 
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(two cleavage stage blastomeres). (B) Follow up result using 24Sure arrays: 
Balanced for the translocation chromosomes; loss of 21 (rest of the embryo). 
The loss of 21 is a whole chromosome meiotic loss as it was present on 
diagnosis and in the rest of the embryo on follow-up. 
 
Figure 6 Analysis of chromosomes involved in meiotic vs mitotic aneuploidy 
events 
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Table 1 Karyotype of carriers of reciprocal and Robertsonian translocations, along with their reproductive histories 
Patient ID  
Karyotype of translocation 
carrier  
PGD 
Cycle 
No. 
Maternal 
Age 
(years) 
Sample type 
tested 
No of 
embryos 
biopsied
§ 
No.  of 
transferrable 
embryos  
Reproductive History 
Reciprocal translocation - male carriers 
A 
 
46,XY,t(1;13)(p34.3;q34) ** 
1 23 Blastomeres 14 (2) 4 No previous attempts at 
IVF 2 23 Blastomeres 9 1 
B 46,XY,t(1;14)(p21.1;q11.2) 1 28 Blastomeres 8 (1) 1 
No previous attempts at 
IVF 
C 
 
46,XY,t(1;19)(p34;q13.1) 
1 34 Blastomeres 20 1 No previous attempts at 
IVF 
No previous 
pregnancies 
2 34 Trophectoderm cells 8  0 
D 
 
46,XY,t(16;20)(q13;q13.3) 
1 32 Blastomeres 7 1 
Primary infertility  
No previous attempts at 
IVF 
Low AMH 
2 32 Blastomeres 4 (1) 2 
E 46,XY,t(9;15)(q33.2;q11.2) 1 35 Blastomeres 5 (1) 2 
Primary Infertility 
1 failed IVF attempt 
1 TOPFA 
1 natural pregnancy 
with balanced 
translocation 
F 46,XY,t(1;6)(p22;q15) 1 35 Blastomeres 22 3 
2 miscarriages 
Previous triplet IVF 
pregnancy reduced and 
birth of a child with 
balanced translocation 
Normal birth from 
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Patient ID  
Karyotype of translocation 
carrier  
PGD 
Cycle 
No. 
Maternal 
Age 
(years) 
Sample type 
tested 
No of 
embryos 
biopsied
§ 
No.  of 
transferrable 
embryos  
Reproductive History 
previous PGD cycle 
G 46,XY,t(1;3)(q31;p13) 1 36 
Blastomeres 
 
 
11 0 
4 failed IVF attempts   
2 miscarriages  
1 previously failed PGD-
FISH cycle  
H 
 
46,XY,t(4;12)(q25;q24.31) 
1 37 Blastomeres 8 0 
2 failed IVF attempts  
1 ectopic pregnancy  
Normal birth from 
previous PGD cycle 2 37 Blastomeres 17 2 
I  46,XY,t(4;10)(q33;q24.1) 1 38 Blastomeres 10 2 
3 first trimester 
miscarriages 
J 46,XY,t(3;4)(q27;q27) 1 40 Blastomeres 4 0 
2 failed IVF attempts  
2 miscarriages  
woman with polycystic 
ovaries. 
K 46,XY,t(11;13)(q21;q14.1) 1 41 Blastomeres 8 1 7 miscarriages 
L 46,XX,t(5;15)(p15.31;q22) 1 34 Blastomeres 5 1 
Primary  infertility 
(duration 9 years) 
Reciprocal translocation - female carriers 
M 46,XX,t(5;7)(q14;q11.2) 
1 35 Blastomeres 19 0 
3 failed IVF attempts 
2 35 Trophectoderm cells 6 2 
N 46,XX,t(12;14)(q24.1;q32.1) 1 38 Blastomeres 4 0 
2 failed IVF attempts 
woman with polycystic 
ovaries.  
O 46,XX,t(11;19)(q14.2;q13.3) 1 39 Blastomeres 3 0 1 miscarriage (8/40),  
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Patient ID  
Karyotype of translocation 
carrier  
PGD 
Cycle 
No. 
Maternal 
Age 
(years) 
Sample type 
tested 
No of 
embryos 
biopsied
§ 
No.  of 
transferrable 
embryos  
Reproductive History 
1 TOPFA with balanced 
karyotype but with 
cloacal abnormality, 
Suboptimal ORT 
P 
 
46,XX,t(11;22)(q23.3;q11.2) 
1 39 Blastomeres 9 (3) 0 
3 miscarriages 
1 TOPFA after 
abnormal CVS result 
with an unbalanced 
form of translocation 
2 39 Blastomeres 13 (1) 2 
Robertsonian translocation - male carriers 
Q 45,XY,der(13;14)(q10;q10) 1 34 Blastomeres  9 2 
Primary infertility 
(duration 2 years) 
3 failed IVF attempts 
R 
 
45,XY,der(13;14)(q10;q10) 
1 37 Blastomeres 9 (1) 1 
Primary infertility  
(duration 2 years)   
2 miscarriages  
Product of conception 
with trisomy 17 
2 37 Blastomeres 5 4 
S 45,XY,der(14;21)(q10;q10) 1 39 Blastomeres 15 (1) 5 
Primary infertility 
(duration 6 years) 
2 failed IVF attempts 
(1 with PGD) 
T 46,XYY,der(14;15)(q10;10) 
1 35 Blastomeres 5 0 
Primary infertility 
(duration 3 years) 
Failed IUIs.  
1 miscarriage after IVF 
cycle 
2 36 Blastomeres 11 (1) 3 
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Patient ID  
Karyotype of translocation 
carrier  
PGD 
Cycle 
No. 
Maternal 
Age 
(years) 
Sample type 
tested 
No of 
embryos 
biopsied
§ 
No.  of 
transferrable 
embryos  
Reproductive History 
U 45,XY,der(14;21)(q10;q10) 1 37 Blastomeres 10 1 
Primary infertility 
(duration 9 years) 
2 failed IVF attempts  
1 miscarriage 
Robertsonian translocation - female carriers 
V 
45,XX,der(14;21)(q10;q10) 
 
1 35 Blastomeres 15 1 
Normal birth from 
previous PGD cycle  
4 undiagnosed 
spontaneous 
pregnancies resulting in 
miscarriage 
W 
 
45,XX,der(13;14)(q10;q10) 1 41 Blastomeres 5 0 4 miscarriages 
ORT =Ovarian Reserve Test,  
TOPFA= Termination of pregnancy with fetal anomaly,  
AMH =anti-mullerian hormone, CVS=chorionic villus sample,  
IUI= Intrauterine insemination.  
IVF attempts refers to cycles without PGD 
**The female partner was a carrier of Crouzon syndrome/OMIM:123500 
§The number in brackets indicates those 12 embryos which did not give a conclusive result on day 3 but gave a result after TE biopsy (day 5/6). 
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Table 2 Diagnostic outcome of the 31 PGD-aCGH cycles for translocation 
carriers 
No. of embryos Reciprocal 
Translocation 
Robertsonian 
Translocation 
Total 
No. biopsied  214 84 298 
No. transferrable 25 17 42/298 (14%) 
No. untransferrable 189 67 256/298 (86%) 
No. with translocation 
related imbalances 
only 
46 13 59/256 (23%) 
No. with translocation 
related imbalances with 
1 – 5 additional 
aneuploidies 
56 14 70/256 (27%) 
No. with 1 – 5 
additional aneuploidies 
only 
28 14 42/256(16%) 
No. with multiple 
chromosome 
aneuploidies (>5 
aneuploidies) 
41 17 58/(256) (23%) 
No. with no results or 
amplification failure 
18 9 27/298 (9%) 
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